Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Macrophages in multiple myeloma: emerging concepts and therapeutic implications

(2013) Fotis Asimakopoulos et al.   LEUKEMIA & LYMPHOMA

The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma

(2012) Walter M. T. Braga et al.   Clinical & Developmental Immunology

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

(2012) J A Katzmann et al.   LEUKEMIA

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients

(2012) A Bradwell et al.   LEUKEMIA

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

(2012) E Kastritis et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations

(2009) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY